ASO therapy has also been investigated in the clinic for spinal muscular atrophy, caused by changes in the SMN1 gene that decrease the SMN protein and disrupt the functioning of motor neurons, affecting muscle control. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.